» Articles » PMID: 35271462

Centrosomal Protein 290 is a Novel Prognostic Indicator That Modulates Liver Cancer Cell Ferroptosis Via the Pathway

Overview
Specialty Geriatrics
Date 2022 Mar 10
PMID 35271462
Authors
Affiliations
Soon will be listed here.
Abstract

Ferroptosis is an iron-dependent form of cell death. In spite of its significance in pathogenesis and disease progression, ferroptotic signal transduction in HBV-HCC has not been fully explained. Here, four HCC open-source datasets were downloaded from the GEO repository. Cox regression and LASSO models were established to prioritize novel prognostic candidate biomarkers, and the results were verified and . We identified 633 common DEGs in both of the bulk RNA-Seq expression profiles. Next, based upon the TCGA-LIHC cohort, a prognostic signature consisting of nine genes was extracted from 633 shared DEGs, and the specificity and sensitivity of the signature were evaluated in both training and validation datasets. This signature showed that the high-risk group had a worse prognosis than the low-risk group. CEP290 was discovered among the prognostic signature genes, and its expression notably correlated with survival, AFP level, TNM stage and vascular invasion. We confirmed expression of CEP290 in eight pairs of HCC tissues and diverse liver cancer cell lines. CEP290 knockdown reduced proliferation, migration and invasion in Hep3B liver cancer cells while Fe2+ and malondialdehyde levels were elevated. Mechanically, co-immunoprecipitation showed an interaction between CEP290 and Nrf2 proteins, and biological phenotypes of Hep3B cells under CEP290 interference were rescued by Nrf2 activator. Furthermore, CEP290 silencing considerably blocked protein expression of Nrf2 pathway members. Finally, suppression of CEP290 effectively inhibited tumor growth . The above results shed light on the important role of CEP290 in ferroptosis and present an important implication for HCC progression.

Citing Articles

Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models.

Jin Y, Chen P, Zhou H, Mu G, Wu S, Zha Z Front Immunol. 2025; 16:1505868.

PMID: 39995668 PMC: 11847686. DOI: 10.3389/fimmu.2025.1505868.


SNRPB and CEP290, predicting the prognosis of diffuse large B cell lymphoma and associated with tumour immune microenvironment.

Tang J, Lu B, Bin T, Xu X, Lin C, Wang Y Ann Med. 2024; 56(1):2425065.

PMID: 39624962 PMC: 11616747. DOI: 10.1080/07853890.2024.2425065.


Ferroptosis: insight into the treatment of hepatocellular carcinoma.

Liao C, He Y, Luo X, Deng G Cancer Cell Int. 2024; 24(1):376.

PMID: 39538215 PMC: 11562710. DOI: 10.1186/s12935-024-03559-z.


Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.

Liu B, Liu L, Liu Y Front Immunol. 2024; 15:1450487.

PMID: 39315094 PMC: 11416969. DOI: 10.3389/fimmu.2024.1450487.


Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer.

Shu Y, Lao B, Qiu Y World J Gastrointest Oncol. 2024; 16(6):2335-2349.

PMID: 38994128 PMC: 11236230. DOI: 10.4251/wjgo.v16.i6.2335.


References
1.
Bartolini D, Dallaglio K, Torquato P, Piroddi M, Galli F . Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Transl Res. 2017; 193:54-71. DOI: 10.1016/j.trsl.2017.11.007. View

2.
Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

3.
Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E . Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel). 2018; 10(12). PMC: 6315366. DOI: 10.3390/cancers10120481. View

4.
Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View

5.
Shelton P, Jaiswal A . The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?. FASEB J. 2012; 27(2):414-23. PMC: 3545532. DOI: 10.1096/fj.12-217257. View